German Grünenthal Group has entered into an agreement to acquire the global rights to AstraZenecas migraine treatment Zolmitriptan.
Belgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.
German Merck KGaA has secured an option on UKs F-Star Biotechnology Ltds preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.
Cambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties.
UK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.
Following a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinsons and ADX71441.
London-based orphan drug developer AMO Pharmas drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy.
French drug delivery specialist Biocorp S.A. (Issoire) has signed an industrialisation contract with Virbac, one of the top-ten vet-med makers.
Janssen speeds up US approval of psoriasis antibody guselkumab and targets further indications.
British Abzena plc has announced that True North Therapeutics (TNT) will be taken over by Bioverativ Inc. Bioverativ will further develop TNT’s complement factor C1-blocking antibody TNT009, developed using technology, which was licenced from Abzenawhich was licenced from Abzena.